SPYRE THERAPEUTICS, INC. Impairment of Leasehold
SPYRE THERAPEUTICS, INC. (SYRE) reported Impairment of Leasehold of $1.70 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-11-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLeasehold · last filed 2026-02-19
- SPYRE THERAPEUTICS, INC. impairment of leasehold for the quarter ending 2023-06-30 was $1.70M.
| Period end | Impairment of Leasehold | Impairment of Leasehold 3 month | Impairment of Leasehold 6 month |
|---|---|---|---|
| 2023-06-30 | $1.70M 10-K · filed 2026-02-19 | $1.70M 10-Q · filed 2023-11-09 | $1.70M 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |